Patents by Inventor Todd Bosanac

Todd Bosanac has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220194933
    Abstract: The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.
    Type: Application
    Filed: June 6, 2019
    Publication date: June 23, 2022
    Inventors: Robert Owen Hughes, Rajesh Devraj, Todd Bosanac, Richard Andrew Jarjes-Pike, Andrew Simon Brearley, Jonathan Bentley
  • Publication number: 20220072019
    Abstract: The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and NAD+ or a NAD+ precursor.
    Type: Application
    Filed: October 18, 2019
    Publication date: March 10, 2022
    Inventors: Todd BOSANAC, Rajesh DEVRAJ, Thomas ENGBER, Robert Owen HUGHES, Raul Eduardo KRAUSS
  • Publication number: 20220056013
    Abstract: The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.
    Type: Application
    Filed: August 23, 2021
    Publication date: February 24, 2022
    Inventors: Todd BOSANAC, Andrew Simon BREARLEY, Rajesh DEVRAJ, Robert Owen HUGHES, Richard Andrew JARJES-PIKE, Shelley Anne PARROTT
  • Publication number: 20220008405
    Abstract: The present disclosure relates to methods of treating neurodegeneration and neurodegenerative diseases comprising administering to a subject in need thereof a combination of a SARM1 inhibitor and a neuroprotective agent.
    Type: Application
    Filed: December 18, 2019
    Publication date: January 13, 2022
    Inventors: Todd BOSANAC, Rajesh DEVRAJ, Thomas ENGBER, Robert Owen HUGHES, Raul Eduardo KRAUSS
  • Publication number: 20210261540
    Abstract: The present disclosure provides compounds and methods useful for inhibiting SARM1 and/or treating and/or preventing neurodegenerative disease or axonal degeneration. The provided SARM1 inhibitors may reduce or inhibit binding of NAD+ by SARM1. Alternatively, provided SARM1 inhibitors bind to SARM1 within a pocket comprising one or more catalytic residues (e.g., a catalytic cleft of SARM1).
    Type: Application
    Filed: June 6, 2019
    Publication date: August 26, 2021
    Inventors: Robert Owen Hughes, Rajesh Devraj, Todd Bosanac, Richard Andrew Jarjes-Pike, Andrew Simon Brearley, Jonathan Bentley
  • Publication number: 20210261537
    Abstract: The present disclosure provides compounds and methods useful for inhibiting SARMI and/or treating and/or preventing axonal degeneration. Provided SARMI inhibitors reduce or inhibit binding of NAD+ by SARMI and SARMI inhibitors bind to SARMI within a pocket comprising one or more catalytic residues (e.g., a catalytic cleft of SARMI).
    Type: Application
    Filed: June 6, 2019
    Publication date: August 26, 2021
    Inventors: Robert Owen Hughes, Rajesh Devraj, Todd Bosanac, Richard Andrew Jarjes-Pike, Andrew Simon Brearley, Jonathan Bentley
  • Patent number: 10975099
    Abstract: The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: April 13, 2021
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri Theodore Moustakas, Thomas Andrew Wynn, Todd Bosanac
  • Publication number: 20210009567
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: July 23, 2020
    Publication date: January 14, 2021
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • Patent number: 10875852
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: December 29, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joerg Bentzien, Angela Kay Berry, Todd Bosanac, Michael Jason Burke, Darren Todd Disalvo, Joshua Courtney Horan, Shuang Liang, Can Mao, Wang Mao, Yue Shen, Fariba Soleymanzadeh, Renee M. Zindell
  • Patent number: 10807995
    Abstract: The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: October 20, 2020
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri T. Moustakas, Thomas Andrew Wynn, Todd Bosanac
  • Publication number: 20200325157
    Abstract: The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Application
    Filed: November 5, 2019
    Publication date: October 15, 2020
    Inventors: Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri Theodore Moustakas, Thomas Andrew Wynn, Todd Bosanac
  • Patent number: 10799496
    Abstract: The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: October 13, 2020
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri T. Moustakas, Thomas Andrew Wynn, Todd Bosanac
  • Patent number: 10624882
    Abstract: Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: April 21, 2020
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Todd Bosanac, John David Ginn, Eugene Richard Hickey, Thomas Martin Kirrane, Jr., Weimin Liu, Anthony S. Prokopowicz, Sabine K. Schlyer, Cheng-Kon Shih, Roger John Snow, Michael Robert Turner, Frank Wu, Erick Richard Young
  • Patent number: 10570118
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, R2, R3, R4 and R5 are defined herein, which are suitable for the treatment of diseases related to Bruton's tyrosine kinase (BTK), and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: February 25, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Todd Bosanac, Joerg Bentzien, Michael Jason Burke, Darren Todd DiSalvo, Wang Mao, Fariba Soleymanzadeh, John A. Westbrook, Zhaoming Xiong
  • Publication number: 20200055843
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: August 29, 2019
    Publication date: February 20, 2020
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • Publication number: 20200016151
    Abstract: The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Application
    Filed: July 11, 2019
    Publication date: January 16, 2020
    Inventors: Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri T. Moustakas, Thomas Andrew Wynn, Todd Bosanac
  • Publication number: 20200017529
    Abstract: The present invention provides compounds useful for the treatment of opioid dependence, alcohol dependence, alcohol use disorder, or the prevention of relapse to opioid dependence in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Application
    Filed: July 11, 2019
    Publication date: January 16, 2020
    Inventors: Brian M. Aquila, Hoan Huynh, Lewis D. Pennington, Ingo Mugge, Baudouin Gerard, Markus Haeberlein, Roman A. Valiulin, Julius F. Remenar, Demetri T. Moustakas, Thomas Andrew Wynn, Todd Bosanac
  • Publication number: 20190263828
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A and B are defined herein, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 29, 2019
    Inventors: Todd BOSANAC, Michael J. BURKE, Brian Nicholas COOK, Darren Todd DISALVO, Thomas Martin KIRRANE, JR., Yue SHEN
  • Patent number: 10364255
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A and B are defined herein, which are suitable for the treatment of diseases related to Vanin, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: July 30, 2019
    Assignee: Boehringer Ingleheim International GmbH
    Inventors: Todd Bosanac, Michael J. Burke, Brian Nicholas Cook, Darren Todd Disalvo, Thomas Martin Kirrane, Jr., Yue Shen
  • Publication number: 20190112302
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.
    Type: Application
    Filed: October 15, 2018
    Publication date: April 18, 2019
    Inventors: Joerg BENTZIEN, Angela Kay BERRY, Todd BOSANAC, Michael Jason BURKE, Darren Todd DISALVO, Joshua Courtney HORAN, Shuang LIANG, Can MAO, Wang MAO, Yue SHEN, Fariba SOLEYMANZADEH, Renee M. ZINDELL